Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

Lu, Hailing, Dietsch, Gregory N., Matthews, Maura-Ann H., Yang, Yi, Ghanekar, Smita, Inokuma, Margaret, Suni, Maria, Maino, Vernon C., Henderson, Katherine E., Howbert, James Jeffry, Disis, Mary L., Hershberg, Robert M.·2012·Clinical Cancer Research

Abstract

Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its potential to improve monoclonal antibody–based immunotherapy that includes the activation of natural killer (NK) cells. Experimental Design: HEK-TLR transfectants were used to compare the selectivity and potency of VTX-2337, imiquimod, CpG ODN2006, and CL075. The ability of VTX-2337 to induce cytokine and chemokine production from human peripheral blood mononuclear cells (PBMC) and activation of specific immune cell subsets was examined. The potential for VTX-2337 to activate NK cell activity through direct and indirect mechanisms was also investigated. Finally, we tested the potential for VTX-2337 to augment antibody-dependent cell-mediated cytotoxicity (ADCC), especially in individuals with low-affinity FcγR3A single-nucleotide polymorphism (SNP). Results: VTX-2337 selectively activates TLR8 with an EC50 of about 100 nmol/L and stimulates production of TNFα and interleukin (IL)-12 from monocytes and myeloid dendritic cells (mDC). VTX-2337 stimulates IFNγ production from NK cells and increases the cytotoxicity of NK cells against K562 and ADCC by rituximab and trastuzumab. Effects of VTX-2337 on NK cells were, in part, from direct activation as increased IFNγ production and cytotoxic activity were seen with purified NK cells. Finally, VTX-2337 augments ADCC by rituximab in PBMCs with different FcγR3A genotypes (V/V, V/F, and F/F at position 158). Conclusions: VTX-2337 is a novel small-molecule TLR8 agonist that activates monocytes, DCs, and NK cells. Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clinical efficacy. Clin Cancer Res; 18(2); 499–509. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-1625

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 176

Metadata

Authors
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., Disis, M. L., & Hershberg, R. M.
Venue
Clinical Cancer Research
Published
2012-01-15
Volume
18
Issue
2
Pages
499-509
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2121810724
Cited by
176
References
4
FWCI
3.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-1625
The paper
Lu, H., Dietsch, G. N., Matthews, M.-A. H., Yang, Y., Ghanekar, S., Inokuma, M., Suni, M., Maino, V. C., Henderson, K. E., Howbert, J. J., Disis, M. L., & Hershberg, R. M. (2012). VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-1625

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.